

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

[Back](#)

MEMORIAL HOSPITAL RESEARCH LABORATORIES

[Refer a Patient](#)

[Refer a Patient](#)

The Charles Rudin Lab

ABOUT US

[Our mission, vision & core values](#)


[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)



Charles M. Rudin, MD, PhD

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.



Featured News

[Scientists Learn More about How Lung Cancer Becomes Resistant to Drugs](#)

By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.



[Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why It's So Aggressive](#)

Stem-like cells that make up only a tiny fraction of the total cells in a lung tumor could be the key to

stopping the disease's deadly spread, say researchers at Memorial Sloan Kettering.

[MSK Scientists Reveal Biology of Shape-Shifting Lung Cancer](#)

Lung cancer has an uncanny ability to change its identity to resist drugs. Researchers are learning what drives these changes.

[View All Featured News](#)

Publications Highlights

[Quintanal-Villalonga A, Durani V, Sabet A, Redin E, Kawasaki K, Shafer M, Karthaus WR, Zaidi S, et al. Exportin 1 inhibition prevents neuroendocrine transformation through SOX2 down-regulation in lung and prostate cancers. Sci Transl Med. \(2023\)](#)

[Rudin CM, Balli D, Lai WV, Richards AL, Nguyen E, Egger JV, Choudhury NJ, Sen T, Chow A, Poirier JT, Geese WJ, Hellmann MD, Forslund A. Clinical Benefit From Immunotherapy in Patients With SCLC Is Associated With Tumor Capacity for Antigen Presentation. J Thorac Oncol. \(2023\)](#)

[Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, Brentjens RJ. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. \(2023\).](#)

[Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, et al. The ectonucleotidase CD39 identifies tumor-reactive CD8⁺ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. \(2023\).](#)

[Chemi F, Pearce SP, Clipson A, Hill SM, Conway AM, Richardson SA, Kamieniecka K, Caesar R, et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer. \(2022\)](#)

[View All Publications](#)

People

Charles M. Rudin, MD, PhD

Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.

MD, PhD, University of Chicago Pritzker School of Medicine

✉ rudinc@mskcc.org

Email Address

🔗 [View physician profile](#)

Physician profile

Members

Fathema Uddin

Graduate Student

Emily Costa

Graduate Student

Álvaro Quintanal
Villalonga

Co-Director, The Charles
Rudin Lab




Kelly
Clarke
Senior Program Manager



Barbara De
Mello
Senior Research Assistant



Vidushi Durani
Graduate Student




Kenta
Kawasaki
Research Fellow



Dennis
Kinyua
Research Technician



Yonit Lavin
Postdoctoral Fellow




Jake June-Koo
Lee
Postdoctoral Fellow



Parvathy Manoj


Lab Manager



Evelyn

Nguyen

Graduate Student



Esther Redin


Resano

Research Fellow



Amin Sabet

Graduate Student



Sohrab Salehi

Postdoctoral Fellow



Harsha Sridhar


Senior Research

Technician



Salomon Tendler

Research Fellow



Hong

Zhong

Research Assistant

Lab Alumni
+

Lab Affiliations
+

Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

Career Opportunities

[Apply now](#) →

Get in Touch

✉ rudinc@mskcc.org
Lab Head Email

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles M. Rudin discloses the following relationships and financial interests:

Amgen
Professional Services and Activities

AstraZeneca

Professional Services and Activities

Bridge Medicines

Professional Services and Activities

D2G Oncology

Professional Services and Activities

Daiichi Sankyo

Intellectual Property Rights

Earli Inc.

Equity

Harpoon Therapeutics, Inc.

Professional Services and Activities

Jazz Pharmaceuticals

Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#). For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center